The recognition, set to be presented at the 2026 Breakthroughs Conference and Exhibition, highlights the impact of Kedrion's latest therapy on patient care. QIVIGY was developed through the company's global manufacturing network and is currently undergoing further clinical study to evaluate its effectiveness across additional patient populations. A committee of clinicians, physicians, and supply chain experts selected the recipient based on the product’s contribution to healthcare quality and patient outcomes.
In section Releases
Kedrion Biopharma to be Honored for QIVIGY Innovation
Premier, Inc. has selected Kedrion Biopharma as an honoree for its upcoming 2026 Supplier Innovation Celebration. The award recognizes the company’s development of QIVIGY, an intravenous immunoglobulin therapy for adults with primary humoral immunodeficiency, which was approved by the U.S. Food and Drug Administration last year.
Bob Rossilli, Chief Commercial Officer at Kedrion, described the award as a validation of the company's decade-long investment in manufacturing and scientific research. Bruce Radcliff, President of Supply Chain Services at Premier, noted that the collaboration aligns with a broader mission to improve healthcare efficiency through novel technologies. Kedrion continues to expand its reach, operating as the world’s fifth-largest provider of plasma-derived products with a footprint spanning over 100 countries.
Comments (0)
No comments yet. Be the first!